Differential Therapeutic Approach in Patients with Clinical Stage of Nonseminomatous Germ Cell Testicular Tumors: Long-Term Experience

AUTHORS

D Ondrus 1 , * , M Ondrusova 2

1 1st Department of Oncology, Comenius University Medical School, St. Elisabeth Cancer Institute, Heydukova 10, 812 50, [email protected], Slovak Republic

2 National Cancer Registry of the Slovak Republic, National Centre of Health Informatics? Department of Cancer Epidemiology, Cancer Research Institute, Slovak Academy of Sciences, Slovak Republic

How to Cite: Ondrus D, Ondrusova M. Differential Therapeutic Approach in Patients with Clinical Stage of Nonseminomatous Germ Cell Testicular Tumors: Long-Term Experience, Iran Red Crescent Med J. Online ahead of Print ; 10(3):163-168.

ARTICLE INFORMATION

Iranian Red Crescent Medical Journal: 10 (3); 163-168
Article Type: Review Article
Received: May 7, 2008
Accepted: June 8, 2008

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background: Surveillance after orchiectomy alone has become popular for the management of clinical stage I nonseminomatous germ cell tumors of the testis (CS I NSGCTT). Efforts to identify patients at high risk of relapse has led to a search for prognostic factors of CS I NSGCTT. The aim of this study was to analyse long-term experiences with different therapeutic approaches in CS I NSGCTT patients according to relapse risk factors.

 

Methods: From 2/1992 to 5/2008, a total of 352 CS I NSGCTT patients were included in the study and stratified into different risk-adapted therapeutic approaches (groups 1-3). 114 patients (group 1) with vascular invasion and majority of embryonal carcinoma component in the primary tumor were treated with 2 cycles of BEP chemotherapy.

 

Results: Relapse was experienced in 2 patients (1.75 %). Among 12 patients (group 2) with vascular invasion and majority of teratomatous elements in the primary tumor undergoing primary retroperitoneal lymph node dissection (RPLND), 10 were found to be in pathological stage I. Relapse was observed in two patients (16.7 %), one of whom died 29 months following orchiectomy. Two patients (18.2 %) with pathological stage II received adjuvant chemotherapy and finally died. 226 patients (group 3) without vascular invasion were followed after orchiectomy. Relapse was observed in 41 patients (18.1 %). They were treated with BEP chemotherapy, of whom three died. The overall survival rate of all the patients in group B1-3 was 98.3 %.

 

Conclusions: Surveillance procedure is recommend only in patients without vascular invasion in the primary tumor.

 

Keywords

Testicular cancer Surveillance Chemotherapy Retroperitoneal space Lymph node Dissection

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: